CD38 Low - Search News

J&J will not exercise worldwide license option for HexaBody-CD38, says Genmab

Genmab A/S said that Johnson & Johnson has decided not to exercise its option to obtain a worldwide license for the development of HexaBody-CD38.

Business Insider · 4d

Genmab falls 7% to $22.44 after J&J declines option on HexaBody-CD38

EDT Genmab (GMAB) falls 7% to $22.44 after J&J declines option on HexaBody-CD38Optimize Your Investment Research with

MarketWatch · 4d

Genmab Shares Fall After J&J Drops Blood-Cancer Treatment Option

Genmab shares fell on Monday after the company said it would end the development of blood-cancer treatment HexaBody-CD38 because Johnson & Johnson won't exercise its option to license it.

Hosted on MSN2mon

MitoThrive Reviews: Does This Formula Truly Reduce Aging Symptoms? Benefits, Results, And Potential Side Effects!

However, an enzyme called CD38 breaks down the NAD, causing it to leak from cells. This leak gets accelerated with age and causes issues of aging and low energy levels. This MitoThrive formula is ...

Investing4d

Genmab reports Johnson & Johnson’s HexaBody-CD38 decision

Copenhagen-based biotech firm Genmab A/S disclosed today that Johnson & Johnson will not advance the HexaBody-CD38 program, as detailed in a recent SEC filing. The announcement was made in a Form ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Trending now